DC4U

Their core work

DC4U is a Dutch biotech SME specializing in glycan-based (carbohydrate) approaches to immune modulation and therapy. Their work spans designing carbohydrate immunomodulators that target immune receptors, developing glycan-allergen immunotherapy for allergy treatment, and addressing immunogenicity challenges in protein therapeutics such as Factor VIII for haemophilia. They bridge glycobiology and clinical immunology, translating carbohydrate science into therapeutic applications across allergy, cancer diagnostics, and rare blood disorders.

What they specialise in

How they've shifted over time

In their early H2020 period (2015-2018), DC4U focused broadly on carbohydrate immunology — designing glycan-based immunomodulators (IMMUNOSHAPE) and exploring glycosylation in cancer (GlyCoCan), while also pursuing their own allergy therapy concept through GAIT. By 2020, their focus narrowed toward a specific clinical application: addressing anti-drug antibody responses and immunogenicity in protein therapeutics, particularly Factor VIII for haemophilia A (EDUC8). This shift suggests a maturation from general glycan immunology toward a defined therapeutic niche in rare disease biologics.

DC4U is moving from broad carbohydrate immunology research toward focused expertise in managing immune responses to biologic drugs, particularly in haemophilia — a high-value niche in the growing biologics market.

How they like to work

DC4U primarily joins consortia as a participant or third party rather than leading them, with only one coordination role (the small GAIT SME Instrument project). They have built a surprisingly broad network for a small company — 34 unique partners across 9 countries through just 4 projects — suggesting they contribute specialized glycan expertise to large training networks (MSCA-ITN). Their typical engagement pattern is as a niche specialist embedded in academic-led consortia.

DC4U has collaborated with 34 unique partners across 9 countries, a wide network built mainly through participation in Marie Curie training networks. Their reach is pan-European, typical of MSCA-ITN consortia that assemble multi-country academic and industry partners for doctoral training.

What sets them apart

DC4U occupies a rare niche at the intersection of glycobiology and therapeutic immunology — few SMEs combine deep carbohydrate chemistry knowledge with direct application to immune modulation in biologics. Their progression from general glycan research to the specific challenge of anti-drug antibodies in protein therapeutics gives them a focused value proposition for pharma and biotech companies developing biologic drugs. For consortium builders, they offer industry-embedded glycan expertise that complements academic immunology groups.

Highlights from their portfolio

• GAIT
  DC4U's only coordinated project — an SME Instrument Phase 1 validating their own glycan-allergen immunotherapy concept for disease-modifying allergy treatment.
• EDUC8
  Their most recent project (2020-2024) marks a strategic pivot into Factor VIII immunogenicity for haemophilia A, a high-value rare disease application.
• IMMUNOSHAPE
  Their largest funded project (EUR 255,374) and earliest H2020 engagement, establishing their core competence in carbohydrate immunomodulators targeting C-type lectin receptors.